The movement to deliver cancer care in resource-limited settings is gaining momentum, with particular emphasis on the creation of cost-effective, rational algorithms utilizing affordable chemotherapeutics to treat curable disease. The delivery of cancer care in resource-replete settings is a concerted effort by a team of multidisciplinary care providers. The oncology pharmacy, which is now considered integral to cancer care in resourced medical practice, developed over the last several decades in an effort to limit healthcare provider exposure to workplace hazards and to limit risk to patients. In developing cancer care services in resource-constrained settings, creation of oncology pharmacies can help to both mitigate the risks to practitioners and patients, and also limit the costs of cancer care and the environmental impact of chemotherapeutics. This article describes the experience and lessons learned in establishing a chemotherapy pharmacy in western Kenya.
KanavosP. The rising burden of cancer in the developing world. Ann Oncol2006; 17(suppl_8): viii15–viii23.
3.
LingwoodRJBoylePMilburnANgomaTArbuthnottJMcCaffreyR. The challenge of cancer control in Africa. Nat Rev Cancer2008; 8(5): 398–403.
4.
KerrDMidgleyR. Can we treat cancer for a dollar a day? Guidelines for low-income countries. N Engl J Med2010; 363: 801–803.
5.
CanTreat International. Scaling up cancer diagnosis and treatment in developing countries: what can we learn from the HIV/AIDS epidemic?. Ann Oncol2010; 21(4): 680–682.
6.
SchragD. The price tag on progress – chemotherapy for colorectal cancer. N Engl J Med2004; 351(4): 317–319.
7.
HesselingPBMolyneuxETchintsemeFWelbeckJMcCormickPPritchard-JonesK. Treating Burkitt’s lymphoma in Malawi, Cameroon, and Ghana. Lancet Oncol2008; 9(6): 512–513.
8.
DedicoatMNewtonR. Treatment of Kaposi’s sarcoma in resource-poor settings. Trop Doct2005; 35(1): 60–60.
9.
HesselingPBroadheadRMansveltELouwMWesselsGBorgsteinE. The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer2005; 44(3): 245–250.
10.
HowardSCPedrosaMLinsMPedrosaAPuiC-HRibeiroRC. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA2004; 291(20): 2471–2475.
11.
OmarS. The Fakous experience: meeting the challenge of cancer in a low resource setting. Breast J2007; 13(3): 318–319.
12.
AndersonMBrassingtonDBolgerJ. Development and operation of a pharmacy-based intravenous cytotoxic reconstitution service. Br Med J (Clin Res Ed)1983; 286(6358): 32–36.
13.
KnowlesRSVirdenJE. Handling of injectable antineoplastic agents. Br Med J1980; 281(6240): 589–591.
14.
SelevanSGLindbohmMLHornungRWHemminkiK. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med1985; 313(19): 1173–1178.
15.
ValanisBVollmerWMLabuhnKGlassACorelleC. Antineoplastic drug handling protection after OSHA guidelines. Comparison by profession, handling activity, and work site. J Occup Med1992; 34(2): 149–155.
16.
ValanisBGVollmerWMLabuhnKTGlassAG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm1993; 50(3): 455–462.
17.
ValanisBVollmerWLabuhnKGlassA. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med1997; 39(6): 574–580.
18.
ValanisBVollmerWMSteeleP. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med1999; 41(8): 632–638.
19.
YodaikenREBennettD. OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Occupational Safety and Health Administration. Am J Hosp Pharm1986; 43(5): 1193–1204.
20.
ISOPP Standards of Practice. Safe handling of cytotoxics. J Oncol Pharm Pract2007; 13(Suppl): 1–81.
21.
Wools-KaloustianKKimaiyoSDieroLSiikaASidleJYiannoutsosCT. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. Aids2006; 20(1): 41–48.
22.
EinterzRMKimaiyoSMengechHNKKhwa-OtsyulaBOEsamaiFQuigleyF. Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med2007; 82(8): 812–818.
23.
EinterzRMKelleyCRMamlinJJVan RekenDE. Partnerships in international health. The Indiana University-Moi University experience. Infect Dis Clin North Am1995; 9(2): 453–455.
24.
25.
MahnikSNRizovskiBFuerhackerMMaderRM. Development of an analytical method for the determination of anthracyclines in hospital effluents. Chemosphere2006; 65(8): 1419–1425.
26.
MbongweBMmerekiBTMagashulaA. Healthcare waste management: current practices in selected healthcare facilities, Botswana. Waste Manag2008; 28(1): 226–233.
27.
FasolaGAitaMMariniLFolladorATosoliniMMattioniL. Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study. BMC Health Serv Res2008; 8(1): 70–70.
28.
FieldKZelenkoAKosmiderSCourtKNgL-LHibbertM. Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs. Asia-Pacific J Clin Oncol2010; 6(3): 203–209.
29.
FeliciAVerweijJSparreboomA. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer2002; 38(13): 1677–1684.
30.
MathijssenRHJde JongFALoosWJvan der BolJMVerweijJSparreboomA. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?. Oncologist2007; 12(8): 913–923.
31.
MwandaWOOremJFuPBanuraCKakemboJOnyangoCA. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin’s lymphoma in East Africa. J Clin Oncol2009; 27(21): 3480–3488.
32.
SterlingLvan LonkhuijzenLNyangenaJOrangoEStrotherMBusakhalaN. Protocol development for ovarian cancer treatment in Kenya: a brief report. Int J Gynecol Cancer2011; 21(2): 424–427.
33.
DranitsarisGTruterILubbeMSSriramanakoppaNNMendoncaVMMahagaonkarSB. Improving patient access to cancer drugs in India: using economic modeling to estimate a more affordable drug cost based on measures of societal value. Int J Technol Assess Health Care2011; 27(01): 23–30.
34.
VanniTFonsecaBAPolanczykCA. Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi’s sarcoma in Brazil. HIV Clin Trials2006; 7(4): 194–202.
35.
KanavosP. The rising burden of cancer in the developing world. Ann Oncol2006; 17(Supplement 8): viii15–viii23.
36.
FarmerPFrenkJKnaulFMShulmanLNAlleyneGArmstrongL. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet2010; 376(9747): 1186–1193.
37.
CarringtonCStoneLKoczwaraBSearleCSiderovJStevensonB. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia-Pacific J Clin Oncol2010; 6(3): 220–237.
38.
ConnorTHMcDiarmidMA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin2006; 56(6): 354–365.
39.
GreenEJohnstonMTrudeauMSchwartzLPoirierSMacartneyG. Safe handling of parenteral cytotoxics: recommendations for Ontario. J Oncol Pract2009; 5(5): 245–249.
40.
LivnehJWaddingtonKBarJ. Addressing safety issues of health care personnel, family members, and the environment. J Clin Oncol2010; 28(13): e209–e209.
41.
TurciRMinoiaC. Residual hazard assessment related to handling of antineoplastic drugs: safety system evolution and quality assurance of analytical measurement. Ann New York Acad Sci2006; 1076(1): 649–656.
42.
IshikawaKKatzMHill-BesinqueK. Graduate programs in advanced pharmacy practice in oncology in Japan. Am J Pharm Educ2010; 74(6
43.
YoshidaJKosakaHNishidaSKumagaiS. Actual conditions of the mixing of antineoplastic drugs for injection in hospitals in Osaka Prefecture, Japan. J Occup Health2008; 50(1): 86–91.
